Parabilis Medicines IPO

FogPharma, based in Cambridge, Mass., was founded in 2016 by several scientists including Gregory Verdine, the company’s chairman and CEO, Weiging Zhou, David Lane, and Gerard Hilinski. The company, which was valued at $406 million in November 2022, is developing a new class of drugs designed to treat cancerous tumors that have remained elusive to other approaches.

In November 2022, FogPharma closed a $178 million Series D round led by a group of investors including Arch Venture Partners and Invus.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Parabilis Medicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Parabilis Medicines

To invest in Parabilis Medicines pre-IPO

Can you invest in Parabilis Medicines pre-IPO?

Parabilis Medicines is a privately held company and is not publicly traded, therefore investing in Parabilis Medicines pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Parabilis Medicines before it goes public?

You can seek to sell your shares in Parabilis Medicines while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Parabilis Medicines shares?

To determine the value of your Parabilis Medicines shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Parabilis Medicines shares. You can also learn more about how to sell your private shares before getting started.

Is Parabilis Medicines a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Parabilis Medicines potential IPO

Will Parabilis Medicines go IPO?

Parabilis Medicines has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Parabilis Medicines’ IPO price?

The Parabilis Medicines IPO price does not exist at this time, as Parabilis Medicines is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Parabilis Medicines register for Forge Markets, today.

When was Parabilis Medicines founded?

Parabilis Medicines was founded in 2016.

What is Parabilis Medicines funding to date?

Parabilis Medicines has raised $868.26MM to date.

Who are Parabilis Medicines’s major investors?

Hbm Healthcare Investments
Sixty Degree Capital
Gv
General Catalyst
Venbio Partners
6 Dimensions Capital
Rock Springs Capital
Nan Fung Group
Venbio
Catalio Capital Management
Boyu Capital
Farallon Capital Management
Wuxi Apptec
Arch Venture Partners
Samsara Biocapital
The Invus Group
Pagsgroup
Deerfield Management
T. Rowe Price
Leerink Partners
Nextech Invest
Cormorant Asset Management
Blue Pool Capital
Invus
Pivotal Life Sciences
Horizons Ventures
Alex Gorsky
Casdin Capital
Ra Capital Management
Lerrink Partners
Milky Way Investments
Symbiosis Capital Management
Fidelity Management & Research
Marshall Wace
Foresite Capital
Milky Way Investments Group
Wuxi Apptec Corporate Ventures
Fidelity
Symbiosis

Parabilis Medicines Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/01/2024 Series E $145MM $xx.xx $491.9MM Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
Price per Share
$xx.xx
Shares Outstanding
23,281,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
11/21/2022 Series D $178MM $xx.xx $406.53MM Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
Price per Share
$xx.xx
Shares Outstanding
16,537,979
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
03/01/2021 Series C $107MM $xx.xx $262.08MM 6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
Price per Share
$xx.xx
Shares Outstanding
7,384,710
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
05/16/2018 Series B $65.51MM $xx.xx $131.82MM 6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
Price per Share
$xx.xx
Shares Outstanding
4,658,112
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
05/25/2016 Series A $11.11MM $xx.xx $37.05MM Deerfield Management
Price per Share
$xx.xx
Shares Outstanding
1,434,062
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Deerfield Management
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.